Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 7 7 7 versus NORLESTRIN 21 2 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 7 7 7 versus NORLESTRIN 21 2 5 50.
ALYACEN 7/7/7 vs NORLESTRIN 21 2.5/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Combination oral contraceptive containing an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate). Inhibits ovulation by suppressing gonadotropin release. Increases viscosity of cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (CrCl 30-50 mL/min).
Norethindrone: 8 hours (terminal); Ethinyl estradiol: 13 hours (terminal). Clinical context: Steady-state achieved after 3-5 days; dosing interval based on once-daily administration.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norethindrone and ethinyl estradiol); fecal: 30-40% via biliary elimination; <1% unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive